Virologist's perspective - Charles Boucher, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Debate case based: Do we need resistance testing in HCV therapy to guide decision making? Con stance (Not available)- Mark Nelson, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective- David Back, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Are there any special populations in treatment of HCV left?- Douglas Dieterich, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HCV chronic infection treatment with DAA: who are the patients that are not achieving sustained virologic response?- R. Valente

International Workshop on HIV & Hepatitis Co-infection 2017

HCV genotype 3 DAA treatment in a cohort of 284 HIV co-infected patients: a multicenter, observational, retrospective portuguese study- D. Seixas

International Workshop on HIV & Hepatitis Co-infection 2017

Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1- P. Buggish

International Workshop on HIV & Hepatitis Co-infection 2017

Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez Cortes

International Workshop on HIV & Hepatitis Co-infection 2017

Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort - L. Cuypers

International Workshop on HIV & Hepatitis Co-infection 2017

Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection- M. Merli

International Workshop on HIV & Hepatitis Co-infection 2017

Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal- A.R. Garrote

International Workshop on HIV & Hepatitis Co-infection 2017

Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences- M. Peters

International Workshop on HIV & Hepatitis Co-infection 2017

Non liver and survival benefits of SVR in HCV - Marion Peters, MD

International Workshop on HIV & Hepatitis Co-infection 2017

The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez

International Workshop on HIV & Hepatitis Co-infection 2017

Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro

International Workshop on HIV & Hepatitis Co-infection 2017

Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili

International Workshop on HIV & Hepatitis Co-infection 2017

HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

What challenges remain in viral hepatitis- Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

NASH and NAFLD in HIV: same or different? - Mariana Machado, MD

International Workshop on HIV & Hepatitis Co-infection 2017

WHO Target 90-90-90 : Achievable for Latin America- Alejandro Afani, MD

Andean Pacific Workshop on HIV & Hepatitis 2017